RNU6-848P

Across TCGA pan-cancer cohorts, RNU6-848P RNA is linked to patient survival in 2 of 34 cancer types, making it the most broadly survival-associated RNU6-848P data layer.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RNU6-848P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RNU6-848P expression acts as an unfavorable survival marker, although some lineages such as PRAD show a favorable association.

STAD and PRAD are the cancer types where RNU6-848P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Tertile	All	0.241	0.727	<.001	63	view →
PRAD	DFS	Quartile	All	0.971	0.919	.032	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

RNU6-848P–STAD (DFS)

Open the STAD breakdown →